Schulz T B, Berstad A, Rydning A, Frislid K
Scand J Gastroenterol. 1984 Jan;19(1):119-21.
Forty-eight patients with endoscopically proven gastric ulcer were treated either with ranitidine tablets, 150 mg twice daily, or with placebo tablets under double-blind conditions. Three patients were for various reasons excluded from the study. After 6 weeks' treatment a second endoscopy was performed. The ulcer had healed in 22 (88%) of the 25 patients who had received ranitidine tablets and in 4 (20%) of the 20 patients who had received placebo tablets. The difference was statistically significant (p less than 0.002). The number of days and nights with pain attacks and the number of antacid tablets consumed were significantly (p less than 0.002) lower in the patient group treated with ranitidine. The 3 patients with non-healed ulcer after treatment with ranitidine had their ulcers healed after a further 6 weeks' treatment with ranitidine, and of the 16 patients with non-healed ulcer after treatment with placebo tablets, 13 had their ulcers healed after 6 weeks' open treatment with ranitidine, 150 mg twice daily. No serious side effects that could be ascribed to treatment occurred during the study.
48例经内镜证实为胃溃疡的患者，在双盲条件下，分别接受每日两次、每次150毫克雷尼替丁片治疗或安慰剂片治疗。3例患者因各种原因被排除在研究之外。治疗6周后进行了第二次内镜检查。接受雷尼替丁片治疗的25例患者中，有22例（88%）溃疡愈合；接受安慰剂片治疗的20例患者中，有4例（20%）溃疡愈合。差异具有统计学意义（p<0.002）。接受雷尼替丁治疗的患者组中，疼痛发作的白天和夜晚次数以及服用的抗酸药片数量均显著降低（p<0.002）。接受雷尼替丁治疗后溃疡未愈合的3例患者，在继续接受6周雷尼替丁治疗后溃疡愈合；接受安慰剂片治疗后溃疡未愈合的16例患者中，13例在接受每日两次、每次150毫克雷尼替丁的6周开放治疗后溃疡愈合。研究期间未出现可归因于治疗的严重副作用。
